256 results about "Bronchial epithelium" patented technology

Methods for treating or preventing asthma (e.g., allergic asthma, asthma associated with allergic bronchopulmonary aspergillosis (ABPA), moderate-to-severe asthma, persistent asthma or the like) and associated conditions (e.g., ABPA, ABPA comorbid with asthma, ABPA comorbid with cystic fibrosis (CF), ABPA comorbid with asthma and CF) in a subject are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided.

The invention relates to a nitric oxide data analysis method and system for bronchial asthma assessment. According to the method, exhaled air nitric oxide and pulmonary alveolar nitric oxide of a patient, omics data and clinical information are acquired in a standardized manner, and multi-dimensional features are constructed after data cleaning and fusion; comprise an inflammation level index, an inflammation region entropy, an inflammation synergy index, a glucocorticoid response factor, an infection-smoking synergy influence factor and a heredity-symptom distribution index. And outputting initial risk assessment based on an explainable elevator EBM model, and finally generating an asthma risk probability through a weighted integration formula to realize three-level layering: low / medium / high risk. The system dynamically associates treatment decisions, for example, the drug dosage and the monitoring frequency are improved when the risk is upgraded, and the medication scheme is optimized when the risk is degraded. According to the scheme, the limitation of traditional single marker static analysis is broken through, multiple mechanisms of dissection, immunity and pharmacology are fused, the evaluation precision and clinical applicability are remarkably improved, the acute attack rate is reduced, and accurate typing treatment is guided.

Intranasal dry powder epinephrine compositions are described herein. The compositions include epinephrine or a pharmaceutically acceptable salt thereof, as well as a stabilizing agent and a carrier. The stabilizing agent is operable to include citric acid, or a pharmaceutically acceptable salt derived therefrom. Such intranasal compositions as described herein are useful in the treatment of health conditions which threaten the central nervous system (CNS) and impede the actions of alpha and beta-adrenergic receptors. Such health conditions include anaphylaxis, bronchospasms, respiratory impairment, organophosphate poisoning, and major adverse cardiac events (MACE).

The invention discloses an intelligent bronchial endoscope focus detection method, computer equipment and a storage medium. The intelligent bronchial endoscope focus detection method comprises the steps that real, reliable and diversified bronchial endoscope examination images are collected; through data preprocessing, labeling and data division, a bronchial focus detection data set is constructed; an efficient bronchial focus detection network is constructed, and improvement is carried out through multiple attention mechanisms and a convolution module; designing a loss function and training the network to obtain an optimized bronchial focus detection model; and performing focus detection on the acquired image in the real-time bronchoscopy video, and displaying a result. Based on the deep learning technology, the deep neural network model is trained to carry out precise focus type detection on the bronchial endoscope image, real-time bronchial lesion prompt information is provided for endoscope operators, the lesion omission problem during bronchial lesion examination is effectively relieved, the bronchoscopy process is standardized, the endoscope examination quality is improved, and the bronchial lesion detection efficiency is improved. And the workload of operators is reduced.

The invention discloses a bronchial asthma symptom intelligent monitoring method and system based on multi-source data, and relates to the technical field of artificial intelligence, and the method comprises the steps: obtaining multi-mode asthma data after time-space alignment; performing weighted fusion on the western medicine index, the environment index, the tongue condition index and the pulse condition index by using a preset pathogenesis mapping rule to generate an asthma pathology state vector; inputting the asthma pathology state vector into an emergency response channel, analyzing abnormal change of short-term peak flow velocity, synchronously inputting into a chronic evolution channel to track long-term change of tongue condition and pulse condition, and generating emergency response integral and syndrome integral; and superposing the emergency response integral and the syndrome integral on a time axis, and triggering risk assessment when the emergency response integral and the syndrome integral meet the time condition coincidence and the peak flow rate declines to reach an early warning threshold value. According to the method, asthma pathology state vectors are respectively input into an emergency response channel and a chronic evolution channel, so that synchronous monitoring and dynamic modeling of acute attack and chronic disease courses are realized.

The invention relates to a plant astragalus membranaceus-derived exosome-like nano-vesicle as well as a preparation method and application thereof. The nano-vesicle is prepared by chopping astragalus membranaceus roots, juicing, carrying out differential-ultra-high-speed centrifugation and filtering. The nano vesicle disclosed by the invention has good biocompatibility and immunomodulatory activity, can be used for intervening bronchial asthma, and shows a relatively good treatment effect; the nano-vesicle can be used as a novel natural plant-derived drug delivery system, and the problems of poor stability, single action mechanism, low delivery efficiency and the like of traditional Chinese medicine components are solved.

The invention relates to an exhaled gas metabolism marker for evaluating attack severity of a bronchial asthma patient and a screening method of the exhaled gas metabolism marker. The marker is acetic acid. The screening method of the exhaled gas metabolism marker for evaluating the severity of the attack of the bronchial asthma patients comprises the following steps: respectively collecting exhaled gas of the bronchial asthma patients with mild continuous attack and moderate continuous attack as analysis samples; analyzing each exhaled gas sample by using HPPI-TOFMS to obtain an original mass spectrum of each exhaled gas sample; preprocessing the original mass spectrum of each expired gas sample to obtain data containing relative intensity information of metabolites; carrying out univariate and multivariate analysis on the data containing the relative intensity information of the metabolites, and screening out differential metabolites; a metabolite with the largest difference is screened out through binary logistic regression analysis, and the metabolite is the marker. The method is simple to operate, can efficiently and objectively evaluate the severity of the attack of the bronchial asthma patient, and has important clinical application value.

The invention discloses application of a neutralizing antibody of oncostatin M in preparation of a medicine for treating bronchial pulmonary dysplasia. The application proves that the intrauterine inflammation can cause BPD-like lung lesion to the filial generation mouse, and the OSM expression level in the mouse lung tissue one day after the intrauterine inflammation filial generation is grown is obviously higher than that of a control group; the OSM level of the BPD group is higher than that of the non-BPD group in the umbilical blood sample of the premature infant; in-vitro experiments show that the OSM treatment can cause lung epithelial cell injury; by dripping a recombined OSM neutralizing antibody into the nose of a newborn mouse, down-regulation of the OSM level in the lung of the mouse is realized, filial generation lung injury induced by the intrauterine inflammation can be repaired, and the OSM can be used as a treatment target of the BPD caused by the intrauterine inflammation.

The application discloses a percutaneous lung puncture path planning method and device based on lung segment level blood vessel structure constraint, and the method comprises the following steps: performing isotropic resampling, lung lobe segmentation and bronchial tree extraction on CT image data to generate a three-dimensional lung dissection model; inputting the three-dimensional lung dissection model into a lung segment semantic segmentation module to output a lung segment boundary; reconstructing the topological connection relationship between lung segment level blood supply arteries and drainage veins from the lung segment boundary to obtain a structured lung segment level blood vessel atlas; constructing a dynamic puncture risk field voxel map according to the structured lung segment level blood vessel atlas; sampling a plurality of candidate needle entry points in a surface feasible needle entry region to generate an initial path set in the three-dimensional lung dissection model; and weighting the path length, cumulative risk value, puncture angle penalty and high-density lung tissue volume according to a multi-objective optimization function to output a final puncture path. The application significantly improves the safety boundary and clinical applicability of percutaneous lung puncture.

A method of testing a test substance in an in vitro model of a human tracheobronchial respiratory tract, includes: providing the in vitro model including a cell culture including airway epithelial cells (AECs), a basolateral compartment below the AECs and an apical compartment above the AECs, wherein the AECs form a barrier between the basolateral AND apical compartments; adding the test substance to the apical and / or basolateral compartment; adding a tracer to the basolateral compartment, which is fluorescent, has a molecular weight within 5 kDa of human albumin and is added before, during or after adding the test substance; incubating the cell culture system in a presence of the tracer; collecting at least one sample from the apical compartment; and measuring a fluorescence thereof to determine an effect of the test substance on the AECs. A kit is also disclosed.

The preservation number of the strain is CGMCC (China General Microbiological Culture Collection Center) NO.30979, the preservation date is June 17, 2024, the preservation classification is named as Lactobacillus brevis, and the preservation unit is the General Microbiological Culture Collection Center of the China Committee for Culture Collection of Microorganisms. The strain is harmless to animals and has the remarkable effects of relieving lung tissue inflammatory infiltration caused by bronchial asthma, reducing release of serum IgE and Th2 type cell factors, inhibiting activation of an NF-kappa B channel and improving allergic airway inflammation. The invention also discloses application of the strain and the thallus component thereof in preparation of drugs for preventing and treating allergic asthma.

Intranasal dry powder epinephrine compositions are described herein. The compositions include epinephrine or a pharmaceutically acceptable salt thereof, as well as a stabilizing agent and a carrier. The stabilizing agent is operable to include citric acid, or a pharmaceutically acceptable salt derived therefrom. Such intranasal compositions as described herein are useful in the treatment of health conditions which threaten the central nervous system (CNS) and impede the actions of alpha and beta-adrenergic receptors. Such health conditions include anaphylaxis, bronchospasms, respiratory impairment, organophosphate poisoning, and major adverse cardiac events (MACE).

Provided herein are methods for diagnosing and treating a pulmonary disease, e.g., bronchopulmonary dysplasia (BPD) using proteomics analysis.

The invention belongs to the technical field of biology, and relates to a bronchoalveolar lavage fluid (BALF) preserving fluid, a kit and a cytological test method. The preservation solution is composed of TCEP, N-acetylcysteine, EDTA.2Na, trehalose, Proclin300, methanol, sodium chloride and HEPES, and all the components have a synergistic effect to achieve sample viscosity removal, oxidation resistance, corrosion prevention, cell protection and pH stabilization. The preserving fluid is suitable for morphological observation and nucleic acid detection of BALF cells, and can stably preserve samples at room temperature and maintain completeness of cell membranes and clear morphological structure. The kit comprises two preparations which are mixed to form a working solution, and the working solution can be directly used for sample preservation on a sampling site. The cytological test method comprises the steps of sample collection, preservation, centrifugal slide preparation, Wright-Giemsa staining and microscopic observation. Experimental results show that preservation solutions of different formulas are compatible with a chromosome system, the cell morphology is kept stable within 3 days, the dyeing effect is good, and it is proved that the preservation system can remarkably improve the preservation stability and detection reliability of BALF samples and is suitable for cytology and molecular diagnosis application of lower respiratory diseases.

The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (I), and sub-formulas thereof: Formula (I) or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatment or prevention of diseases including heart (e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory (e.g.,respiratory infection, acute respiratory distress syndrome), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease, inflammatory bowel disease (IBD), ischemic reperfusion injury (e.g., stroke), retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD), and white matter injury (WMI).

The present invention provides methods and compositions for the treatment of chronic lung disease (CLD), comprising administering to a subject in need of treatment a composition comprising insulin-like growth factor-1 (IGF-1).

The invention relates to the technical field of biology, and particularly discloses application of LLPH as a lung cancer diagnosis biomarker and a treatment target spot, an LLPH expression inhibitor is an LLPH gene knockout plasmid and a genetic engineering construct containing sgRNA and a carrier, the LLPH expression inhibitor is suitable for CRISPR / Cas system mediated gene editing, the sgRNA sequence is 5 '-CTAAAGCTTACGGAGTAAG-3', the carrier is pX459M, and the enzyme cutting site is BbsI-BbsI; by detecting the relative expression quantity of LLPH in normal lung bronchial epithelial cells and lung cancer cell lines, it is found that LLPH is highly expressed in the lung cancer cell lines, and it is shown that LLPH is closely related to lung cancer development. The invention can provide a new biomarker for diagnosis of lung cancer. Lung cancer A549 and H1299 cells are used as models, and the LLPH gene is knocked out, so that the in-vitro malignant proliferation capacity of the lung cancer cells A549 and H1299 can be remarkably inhibited, and LLPH can be used as a potential treatment target for inhibiting lung cancer proliferation.

The invention relates to a CT image data processing method and device, a storage medium and electronic equipment, and belongs to the technical field of data processing, and the method comprises the steps: generating a plurality of training sets according to the combination of the types of bronchiectasis lesions, different training sets comprising CT image data corresponding to different types of combinations of bronchiectasis lesions, the first annotation information comprises a bronchiectasis lesion included in the CT image and the type of the bronchiectasis lesion; according to the plurality of training sets in sequence, training to obtain a first processing model; acquiring CT image data of the lung; inputting the CT image data into a first processing model to obtain a bronchiectasia focus output by the first processing model and determined according to the CT image data, and the type of the bronchiectasia focus; and outputting a processing result of the CT image data according to the determined bronchiectasis focus and the type of the bronchiectasis focus.

The invention provides an atomizing bottle for treating bronchial asthma, and belongs to the technical research field of medical instruments. In order to solve the problem that liquid medicine cannot be effectively sprayed out after being pressed once after an existing dosing device is used for many times, a medicine storage bottle pressurizing mechanism and a to-be-sprayed cylinder are additionally arranged between a medicine spraying pressing rod and a medicine storage bottle; during use, the medicine spraying pressing rod pressurizes the medicine storage bottle for multiple times through the medicine storage bottle pressurizing mechanism while spraying quantitative medicine liquid in the to-be-sprayed barrel from the nozzle, so that enough medicine liquid in the medicine storage bottle is extracted into the to-be-sprayed barrel, and therefore, in emergency medicine application, it can be guaranteed that the enough and quantitative medicine liquid is sprayed out after a patient presses the medicine liquid once.

The invention uses ex vivo human airway cultures to assess the transmissibility and replication ability of influenza and coronavirus strains. By comparing the pandemic influenza A H1N1 and the highly pathogenic influenza A H5N1 as reference virus strains, the spreading risks of various viruses are evaluated and classified. In addition, an in vitro model is used to assess the degree of alveolar fluid clearance (AFC) impairment caused by the virus as an indicator of the severity of the disease. The research reveals the relevance among the virus replication ability, human transmission, AFC damage degree and clinical disease severity of different influenza and coronavirus strains in bronchus.

The present application discloses a bronchial tree model completion method, device and non-volatile storage medium. The method includes: determining a first bronchial tree model, wherein the first bronchial tree model is a model to be completed constructed based on electronic computed tomography data; determining a first target point, and determining a second target point in the first bronchial tree model, wherein the first target point is a point outside the first bronchial tree model, and the second target point is the point on the first bronchial tree model that is closest to the first target point; determining a target center point corresponding to the second target point; completing the first bronchial tree model based on the first target point and the target center point to obtain a second bronchial tree model. The present application solves the technical problem of being unable to accurately determine the patient's bronchial tree structure due to the incomplete bronchial branching structure of the bronchial tree model generated in the related art.

The invention provides modRNA (Ribonucleic Acid) for treating obliterated bronchitis, and belongs to the technical field of bioengineering. The modRNA for treating obliterated bronchitis provided by the invention is composed of an IL-10 modRNA (Interleukin-10) and an IFN (Interferon)-alpha modRNA (Interferon-alpha) modRNA. The BO treatment effect is achieved by inhibiting bronchial epithelial cell epithelial-mesenchymal transition (EMT), the expression of alpha-SMA and Vimentin in lung tissue can be remarkably reduced, the expression of E-cadherin and Cytokeratin 5 can be up-regulated, microbronchial epithelial injury is repaired, collagen deposition is reduced, and the lung function is improved. The synergistic effect of the two is better than that of single gene therapy, the safety is high, and the controllability is strong.

The invention discloses a bronchial lung dysplasia severity prediction method and related equipment, and belongs to the technical field of machine learning, and the method comprises the steps: obtaining the clinical data of a target object; preprocessing the clinical data of the target object, constructing a training set and a verification set according to a preset proportion, and screening to obtain a target variable; based on the target variable, constructing a plurality of bronchial lung dysplasia severity prediction models by using the training set, and performing model performance evaluation on the plurality of constructed bronchial lung dysplasia severity prediction models in the verification set; and obtaining a bronchial lung dysplasia severity prediction model with the optimal performance so as to complete bronchial lung dysplasia severity prediction. The clinical data of the target object is combined with the machine learning algorithm, so that the dynamic change of the immune system of the premature infant can be reflected more comprehensively, the prediction accuracy of the severity of early bronchial pulmonary dysplasia is improved, and scientific data support is provided for clinical treatment selection.

The invention relates to the technical field of biological medicines, in particular to application of a CD20 inhibitor in treatment of chronic obstructive pulmonary diseases. The CD20 inhibitor can remarkably improve emphysema and small airway collagen deposition in chronic obstructive pulmonary diseases, inhibit expression of inflammatory factors IL-6 and TNF-alpha in lung tissue, reduce the concentration of chemotactic factors CXCL2 in bronchoalveolar lavage fluid and relieve lung inflammation, and the treatment effect is remarkable. Obviously, CD20 can become a potential clinical treatment target of chronic obstructive pulmonary disease.

The invention discloses a preparation method of a pyridopyrimidine compound and application of the pyridopyrimidine compound in preparation of an asthma medicine. The pyridopyrimidine compound provided by the invention is applied to preparation of medicines for preventing / treating asthma, DPPO is applied to prevention and treatment of bronchial asthma, and a new medicine choice is brought to asthma patients. Experimental results show that the DPPO can obviously inhibit attack of asthma and secretion of related inflammatory factors such as IL-1beta, IL-4, IL-5, IL-6, IL-13 and IL-17A, has a relaxation effect on tracheal smooth muscles, has the effects of resisting angiogenesis, airway remodeling and inflammation, and achieves the effect of treating asthma. In addition, current researches show that the asthma pathogenesis is very complex, DPPO can obviously improve pathological changes of mouse lung tissues sensitized by house dust mite extract (HDM) and toluene diisocynate (TDI), and the DPPO has certain universality and can be speculated to have huge application potential in research and development of drugs for treating various asthma.

The invention relates to the technical field of medical image processing, and discloses a chronic obstructive pulmonary emphysema distribution quantitative method and system based on multi-scale segmentation, and the method comprises the steps: carrying out the anisotropic diffusion filtering noise reduction of a chest CT image; segmenting a lung field and removing a blood vessel bronchial structure by adopting a region growing algorithm; multi-scale image representation is constructed based on a Gaussian pyramid, an emphysema candidate area is identified in a coarse scale layer, and a boundary is accurately drawn by adopting a self-adaptive threshold value in a fine scale layer; extracting local texture features to distinguish the lobular central emphysema and the total lobular emphysema; dividing severity levels according to spatial aggregation characteristics and density gradient distribution, and calculating an air swelling volume ratio and a distribution heterogeneity index; the three-dimensional pseudo-color volume is used for drawing visualization, a structured quantitative report is generated, accurate segmentation and subtype classification of the emphysema area are achieved, and comprehensive quantitative analysis indexes are provided.

The invention belongs to the technical field of animal model construction, and particularly relates to a construction method and application of a bronchiectasis animal model. According to the method, the bronchiectasis animal model is constructed in a manner of alternately infecting the animal with the self-separated pseudomonas aeruginosa and injecting the protease into the airway of the animal, so that the stable bronchiectasis animal model is successfully obtained, and the modeling success rate is relatively high. It is confirmed through imaging and pathological detection means that the constructed bronchiectasia animal model meets the diagnostic standard of bronchiectasia, chronic pseudomonas aeruginosa airway infection in bronchiectasia can be accurately simulated, structural changes of bronchiectasia are copied, and auxiliary clinical research and application are facilitated.

The utility model belongs to the field of in-vitro cell culture and exposure, and particularly relates to a cell culture exposure unit, a cell culture exposure device and a bionic breathing type exposure system. The cell culture exposure unit is provided with a microporous membrane, a gas chamber and a liquid chamber, the gas chamber and the liquid chamber are located on the two sides of the microporous membrane respectively, a refining baffle is arranged at the position, close to the microporous membrane, in the liquid chamber, and the refining baffle is provided with a microporous structure used for refining CO2 exhaled by the CO2 exhaling device. And the plate surface of the refining baffle plate faces the microporous membrane within the range of the plate surface. The device can better simulate that CO2 in the body stably and naturally passes through a gas-blood barrier, can adapt to different hierarchical positions and shunt flow of a bronchial tree, and is more objective and real in bionic simulation of inhalation exposure and in-vivo environment, thereby being beneficial to obtaining more real and scientific research results.

The invention belongs to the field of biology, and discloses a multiple primer probe set and application thereof. Wherein the multiple primer probe group comprises corresponding primers and probes for detecting seven respiratory tract infection pathogens including canine distemper virus, canine adenovirus type 2, canine parainfluenza virus, canine influenza virus, canine respiratory tract coronavirus, new coronavirus and bordetella bronchiseptica, and the invention also discloses a kit for detecting the respiratory tract infection pathogens including canine distemper virus, canine adenovirus type 2, canine parainfluenza virus, canine influenza virus, canine respiratory tract coronavirus, new coronavirus and bordetella bronchiseptica. The kit is composed of a qPCR reaction solution A1, a qPCR reaction solution A2, an enzyme system mixture, a positive quality control product and a negative quality control product. In the application, the multiple qPCR kit is simple to operate and short in consumed time, the seven different common respiratory tract infection pathogens can be detected at one time through a two-tube reaction system, and the lowest detectable concentration of the seven respiratory tract infection pathogens is 0.1 copies / uL, so that the kit is suitable for clinical rapid detection of the respiratory tract pathogens; and timely and correct treatment aiming at infected pathogens is facilitated.

Intranasal dry powder epinephrine compositions are described herein. The compositions include epinephrine or a pharmaceutically acceptable salt thereof, as well as a stabilizing agent and a carrier. The stabilizing agent is operable to include citric acid, or a pharmaceutically acceptable salt derived therefrom. Such intranasal compositions as described herein are useful in the treatment of health conditions which threaten the central nervous system (CNS) and impede the actions of alpha and beta-adrenergic receptors. Such health conditions include anaphylaxis, bronchospasms, respiratory impairment, organophosphate poisoning, and major adverse cardiac events (MACE).